Enhanced Sensitivity to Chemotherapy in Esophageal Cancer through Inhibition of NF-κB

Journal of Surgical Research

Volumn 132, Issue 1, 2006, Pages 112-120

  Li, Jing ^a   Minnich, Douglas J ^a   Camp, Ernest R ^a   Brank, Adam ^a   MacKay, Sally L D ^a   Hochwald, Steven N ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

5 FU; adenovirus; esophageal cancer; NF B; taxotere

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; CASPASE 7; DOCETAXEL; FLUOROURACIL; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; ESOPHAGUS CANCER; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; REPRESSOR GENE; VIRUS INFECTIVITY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; GENES, REPORTER; HUMANS; KINETICS; LUCIFERASES; NF-KAPPA B; TAXOIDS;

EID: 33646011538     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2005.10.005     Document Type: Article

References (20)

1. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer Statistics. CA A Cancer J for Clin 50 (2000) 7
2. Lee C.T., Seol J.Y., Lee S.Y., et al. The effect of adenovirus-IkappaBalpha transduction on the chemosensitivity of lung cancer cell line with resistance to cis-diaminedichloroplatinum (II) (cisplatin) and doxorubicin (adriamycin). Lung Cancer 41 (2003) 199
3. Pratt W.B. The Anticancer Drugs. ed. 2. (1994), Oxford University Press, New York
4. Fujita N., and Tsuruo T. Survival-signaling pathway as a promising target for cancer chemotherapy. Cancer Chemother Pharmacol 52 (2003) S24
5. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 3 (2003) 17
6. Mader R.M., Muller M., and Steger G.G. Resistance to 5-fluorouracil. Gen Pharmacol 31 (1998) 661
7. Lin A., and Karin M.N.F. NF-kappaB in cancer. A marked target. Semin Cancer Biol 13 (2003) 107
8. Wang W., McLeod H.L., and Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 104 (2003) 504
9. Cusack Jr. J.C., Liu R., Houston M., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341. Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61 (2001) 3535
10. Weaver K.D., Yeyeodu S., Cusack Jr. J.C., Baldwin Jr. A.S., and Ewend M.G. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neuroonc 61 (2003) 187
11. Voboril R., Hochwald S.N., Wessels F., et al. Enhanced chemosensitivity to 5-fluorouracil in colorectal cancer by inhibition of NF-κB. J Surg Res 120 (2004) 178
12. Karin M. The beginning of the end. IκB kinase (IKK) and NF-κB activation. J Biol Chem 274 (1999) 27339
13. Jobin C., Panja A., Hellerbrand C., et al. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J Immunol 160 (1998) 410
14. Poorter R., Peters G.J., Bakker P.J., et al. Intermittent continuous infusion of 5-fluorouracil and low dose oral leucovorin in patients with gastrointestinal cancer. Relationship between plasma concentrations and clinical parameters. Eur J Cancer 31A (1995) 1465
15. Fakih M.G., Creaven P.J., Ramnath N., et al. Phase I and pharmacokinetic study of weekly clocetaxel cisplatin, and daily copecitabine in patients with advanced solid tumors. Clin Cancer Res 11 (2005) 5942
16. Cusack Jr. J.C., Liu R., and Baldwin Jr. A.S. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Res 60 (2000) 2323
17. Hellin A.C., Calmant P., Gielen J., Bours V., and Merville M.P. Nuclear factor-kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene 16 (1998) 1187
18. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6853
19. Fahy B.N., Schlieman M.G., Mortenson M.M., Virudachalam S., and Bold R.J. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 56 (2005) 46
20. Camp E.R., Li J., Minnich J., et al. Inducible NF-κB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 199 (2004) 249